AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership

AstraZeneca Announces The Opening Of Its Newest Global Strategic Research And Development Center, In Kendall Square, Cambridge, Massachusetts; Co. invests $1B To Grow Massachusetts Workforce By Over 50%

$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicinesAstraZeneca today announced the opening of its newest global strategic research and development

Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock

Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity

Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.

Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer

Tenosynovial Giant Cell Tumor (TGCT) - Market Insights, Epidemiology, and Forecast - 2036 | 7MM Market to Reach USD 3.34 Billion as CSF1R Therapies Drive 20.8% CAGR

The TGCT market is projected to grow from USD 326 million in 2025 to USD 3.34 billion by 2036, driven by a 20.8% CAGR. CSF1R-targeted therapies like pexidartinib (TURALIO) and vimseltinib (ROMVIMZA) are transforming treatment, with emerging candidates including pimicotinib and emactuzumab expected to capture significant market share. The US remains the largest market, with surgery continuing as the primary first-line treatment for localized disease while systemic therapies expand for advanced cases.

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

Avacta announced positive Phase 1 clinical data for AVA6103, its next-generation FAP-targeted peptide-drug conjugate, demonstrating a clean safety profile with controlled-release exatecan at doses 50% higher than conventional exatecan's MTD. Pharmacokinetic data aligned with preclinical predictions, and head-to-head preclinical comparisons showed AVA6103 delivered superior antitumor activity compared to marketed ADC Enhertu®, with deep and durable responses in all treated animals.